All companies › EHC

EHC · Encompass Health Corp

Everything on this page is public record — SEC Form 4 filings and congressional disclosures — alongside any INSIDER SCANNER research case for this company.

Open-market buys0
Open-market sells2
Research cases0
Last filing2026-08-31

Insider flow: Selling only — a count of disclosed transactions, not a rating or a recommendation.

Insider transaction timeline

Every reported transaction, positioned by trade date. Purchases sit above the axis, sales below; circle area is proportional to dollar value. No share-price line is drawn — this feed carries transaction prices only, and a price history inferred from them would imply market data the filings do not contain.

Open-market purchase Open-market sale
2026-08-31 — Darby John Patrick · sold 4,858 @ $121.09 2026-08-31 — Price Andrew L · sold 5,211 @ $120.93
2026-08-312026-08-31

Insider participation

One row per insider, one cell per reported transaction, shaded by value. Repeat buying and activity clustered in time are visible at a glance.

Darby John Patrick EVP, Gen Counsel & Secretary
Price Andrew L Chief Accounting Officer
Included with a free account

The analysis built on top of these filings

The filings above are public record and stay public here. What an account adds for $EHC is the reading of them — and for this company, that is what the list below says it is, no more.

  • Transaction timelineThe [{'transaction_date': '2026-08-31', 'insider_name': 'Darby John Patrick', 'insider_title': 'EVP, Gen Counsel & Secretary', 'transaction_type': 'Open-market sell', 'shares': 4858.0, 'price': 121.09, 'value': 588255.22, 'is_buy': False}, {'transaction_date': '2026-08-31', 'insider_name': 'Price Andrew L', 'insider_title': 'Chief Accounting Officer', 'transaction_type': 'Open-market sell', 'shares': 5211.0, 'price': 120.93, 'value': 630166.23, 'is_buy': False}] reported transactions plotted over the window rather than listed, so concentration is visible.

Not available for EHC today: no reported open-market purchases in this window, so there is no insider cost basis to compute; no research case — nothing here has cleared the scoring threshold. Both appear on this page on their own if that changes.

A free account opens all of it.

Not financial advice. This page reports public filings and past research output. It is not a recommendation to buy or sell, and no price target here is a prediction. Trade at your own risk.